43. Kridofos Injection 2ml 1’s

What Is KRIDOFOS INJECTION?

Kridofos Injection is a dual-ester betamethasone corticosteroid combining two different forms of betamethasone in a single 2ml vial, making it one of the most clinically versatile injectable steroids available.

Betamethasone Sodium Phosphate (2mg/ml) is the soluble, fast-acting ester that dissolves rapidly after injection, enters the bloodstream quickly, and begins providing anti-inflammatory and immunosuppressive effects within hours. This gives patients fast, early relief.

Betamethasone Dipropionate (5mg/ml) is the sparingly soluble depot ester that forms a local reservoir at the injection site, releasing betamethasone slowly and steadily over days to weeks, providing prolonged, sustained anti-inflammatory action long after the fast-acting component has been cleared.

What Is It Used For?

Kridofos Injection is used in hospital and specialist clinic settings for musculoskeletal conditions, where it is injected directly into inflamed joints (intra-articular) to provide targeted relief for rheumatoid arthritis flares, osteoarthritis, bursitis, tendinitis, and synovitis, avoiding the systemic side effects of oral steroids while delivering high local concentrations where they are needed most.

As a systemic intramuscular injection, Kridofos Injection is used for acute severe allergic reactions (where parenteral treatment is preferred), severe asthma exacerbations requiring rapid steroid intervention, inflammatory skin conditions such as psoriasis flares and widespread eczema, and acute gout where oral treatment is not feasible.

For skin conditions, intradermal or intralesional injection is used for keloids, alopecia areata, hypertrophic scars, and localised psoriatic plaques.

In Kenya, Kridofos Injection is used across hospital rheumatology, orthopaedics, emergency medicine, and dermatology departments, providing a potent, dual-action injectable corticosteroid option where both immediate and sustained steroid effects are clinically required.

Administration

Administered ONLY by a trained healthcare professional (doctor, clinical officer, or nurse) under sterile conditions. Never for self-administration.

NOT for IV Use

Kridofos must NEVER be given intravenously (into a vein). IV administration of betamethasone dipropionate can cause fatal cardiovascular collapse.

IM Systemic Dose

1–2ml (7–14mg) given as a deep intramuscular injection, typically into the gluteal muscle. May be repeated every 3–4 weeks based on clinical response.

Intra-articular Dose

Dose depends on joint size: Large joints (knee, hip, shoulder): 1–2ml. Medium joints (ankle, elbow, wrist): 0.5–1ml. Small joints (fingers, toes): 0.25–0.5ml.

Intradermal / Intralesional

0.2ml per injection site for skin conditions such as keloids; typically not more than 1ml per session.

Frequency

Frequency is determined by the prescribing clinician based on clinical response and condition. Intra-articular injections are generally limited to 3–4 times per year in the same joint.

Pre-hydration

Not required for IM or intra-articular use (unlike IV bisphosphonates). However, ensure the patient is not significantly dehydrated before systemic dosing.

Common Side Effects

·       Transient post-injection pain or flare at the injection site (especially intra-articular, may last 24–48 hours)

·       Facial flushing (within hours of injection, usually settles within a day)

·       Significant elevation in blood glucose lasting 2–4 weeks (most pronounced in diabetic patients)

·       Mood changes, euphoria, irritability, or insomnia shortly after injection

·       Menstrual irregularities following systemic IM dosing in women

Uncommon Side Effects

·       Skin depigmentation or atrophy at injection site (especially with intradermal use)

·       Weight gain and fluid retention with repeated systemic doses

·       Hypertension with multiple systemic injections

·       Cushing's syndrome features with frequent repeated doses

Serious Side Effects, Seek Immediate Medical Attention

·       Septic arthritis, if intra-articular injection is performed without strict sterile technique (a rare but serious complication)

·       Adrenal suppression, with repeated systemic doses, the body's own cortisol production is suppressed; abrupt cessation can cause adrenal crisis

·       Avascular necrosis of bone, particularly the femoral head, with high-dose or repeated use

·       Tendon rupture, especially if inadvertently injected directly into a tendon rather than the tendon sheath

·       Serious systemic infections; betamethasone masks signs of infection and impairs immune response; close monitoring is essential

·       Fatal cardiovascular collapse if administered intravenously; NEVER give IV

·       NEVER GIVE IV: This is the single most critical safety warning for Kridofos. Betamethasone Dipropionate is insoluble and must never be injected intravenously. IV administration causes cardiovascular collapse and death. All administering clinicians must be explicitly aware of this.

·       DIABETES: Kridofos causes marked, prolonged elevation of blood glucose that can persist for 2–4 weeks after a single injection. Diabetic patients require intensified blood glucose monitoring and likely temporary adjustment of their antidiabetic therapy.

·       INFECTION MASKING: Corticosteroids suppress the immune system and mask the signs and symptoms of infection. Carefully screen for and rule out any active infection before injecting. Monitor closely post-injection.

·       ADRENAL SUPPRESSION: Repeated systemic injections suppress the hypothalamic-pituitary-adrenal (HPA) axis. Patients who have received multiple injections should not have corticosteroids abruptly withdrawn; this can precipitate adrenal crisis.

·       PREGNANCY: Betamethasone crosses the placenta. While betamethasone is intentionally used to accelerate fetal lung maturity in threatened preterm labour, use in other indications during pregnancy requires careful risk-benefit assessment.

·       STERILE TECHNIQUE: Intra-articular injection without strict aseptic technique risks introducing infection into the joint space, septic arthritis is a devastating complication.

·       OSTEOPOROSIS: Repeated use increases fracture risk. Calcium and Vitamin D supplementation is recommended for patients receiving repeated injections.

·       PAEDIATRICS: Growth suppression with repeated dosing in children; use minimum effective dose for shortest necessary duration.

NSAIDs (ibuprofen, diclofenac, naproxen): Additive risk of gastrointestinal ulceration and bleeding; consider proton pump inhibitor cover for concurrent use.

Antidiabetics and Insulin: Betamethasone causes significant hyperglycaemia; adjust antidiabetic doses and monitor blood glucose closely for 2–4 weeks post-injection.

Anticoagulants (Warfarin): Corticosteroids may unpredictably alter INR; monitor more frequently after injection.

CYP3A4 inhibitors (ketoconazole, itraconazole, erythromycin, ritonavir): Increase betamethasone plasma levels by reducing its metabolism, enhancing steroid effect and side effects.

CYP3A4 inducers (Rifampicin, Phenytoin, Carbamazepine, Phenobarbitone): Reduce betamethasone efficacy by accelerating its metabolism; may need to consider alternative or adjust timing.

Live vaccines (BCG, yellow fever, typhoid oral, MMR): Do not administer live vaccines for at least 3 months following systemic corticosteroid injection.

Immunosuppressants (Cyclosporine, Tacrolimus, Methotrexate): Additive immunosuppression, increased risk of serious infection.

Cardiac glycosides (Digoxin): Electrolyte disturbances (hypokalaemia) from corticosteroids increase digoxin toxicity risk, monitor potassium and digoxin levels.

Loop diuretics (Furosemide) and Thiazides: Additive potassium loss, risk of hypokalaemia, which can precipitate arrhythmias.

·       Store at 15–25°C, do NOT freeze. Freezing will destroy the suspension.

·       Protect from light, store in original packaging until use.

·       Do not use if the suspension appears abnormally discoloured or contains unusual particles.

·       For healthcare facility storage only, not for patient home storage.

·       Keep out of reach of children.

·       Observe the expiry date on each vial.

·       Once opened, use immediately, do not store a partially used vial.

Kridofos Injection is a prescription-only injectable corticosteroid (POM) in Kenya. It must be prescribed by a registered medical practitioner and administered exclusively by a trained healthcare professional under appropriate clinical conditions.

Available at Pharmily for dispensing to licensed health facilities and practitioners with a valid prescription.

Kridofos Injection is a dual-ester betamethasone (Betamethasone Dipropionate 5mg/ml + Betamethasone Sodium Phosphate 2mg/ml), equivalent to Diprofos (Merck/Schering) and Celestone Soluspan, which are the internationally recognised originator products using this same dual-ester formulation.

This is a distinct and clinically superior product to single-ester preparations such as Depo-Medrol (methylprednisolone acetate), communicate this distinction clearly when dispensing. The absolute IV contraindication is the paramount safety warning; all healthcare professionals handling or administering this product must be explicitly counselled on this.

The betamethasone dipropionate ester is insoluble, and its intravenous administration has caused fatal outcomes. Diabetes counselling is essential; a single 2ml IM dose of Kridofos causes clinically significant hyperglycaemia lasting 2–4 weeks.

Coordinate with the patient's diabetes care team at the time of dispensing. Sterile technique for intra-articular administration must be confirmed with the administering clinician; septic arthritis following non-sterile intra-articular injection is a devastating and entirely preventable complication.

For patients receiving repeated injections, counsel on the need for calcium and Vitamin D supplementation to protect bone health, and flag the cumulative adrenal suppression risk. Document every dispensing with the vial batch number, patient or facility details, and counselling provided; traceability is essential for a high-risk injectable product.

Q1: What is Kridofos Injection used for?

A: Kridofos is a powerful anti-inflammatory steroid injection used to treat inflammation in joints (for conditions like arthritis, bursitis, and tendinitis), severe allergic reactions, asthma flares, inflammatory skin conditions like keloids, and other conditions requiring rapid and sustained steroid action. It is given by a doctor or nurse, never at home.

Q2: How does Kridofos work differently from a regular steroid injection?

A: Kridofos contains two forms of betamethasone in a single vial. The first (Betamethasone Sodium Phosphate) dissolves and works quickly, providing relief within hours. The second (Betamethasone Dipropionate) forms a slow-release depot at the injection site, providing sustained anti-inflammatory action for days to weeks. This dual action is what makes Kridofos particularly effective.

Q3: How long does a Kridofos injection last?

A: The immediate effect begins within hours of injection. The sustained depot effect typically provides meaningful anti-inflammatory action for 3–4 weeks or longer, depending on the dose, injection site, and individual response.

Q4: Can Kridofos be given as a drip (intravenously)?

A: Absolutely not. Kridofos must NEVER be given intravenously; IV administration has caused serious harm and death. It is given only as a deep intramuscular injection, directly into a joint, into the skin, or around tendons, always by a trained healthcare professional.

Q5: I have diabetes, what happens to my blood sugar after a Kridofos injection?

A: Betamethasone in Kridofos significantly raises blood glucose levels, often for 2–4 weeks after injection. 

Q6: How often can I receive a Kridofos injection into the same joint?

A: Most specialists limit intra-articular injections to 3–4 times per year in the same joint. Repeated injections too frequently can damage the joint cartilage and surrounding tissues. Your doctor will balance the benefit against these risks.